These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30691648)

  • 1. Kinetic characterization of Cas9 enzymes.
    Liu MS; Gong S; Yu HH; Taylor DW; Johnson KA
    Methods Enzymol; 2019; 616():289-311. PubMed ID: 30691648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence.
    Babu K; Kathiresan V; Kumari P; Newsom S; Parameshwaran HP; Chen X; Liu J; Qin PZ; Rajan R
    Biochemistry; 2021 Dec; 60(49):3783-3800. PubMed ID: 34757726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Insights Revealed by the Kinetic Mechanism of CRISPR/Cas9.
    Raper AT; Stephenson AA; Suo Z
    J Am Chem Soc; 2018 Feb; 140(8):2971-2984. PubMed ID: 29442507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical characterization of RNA-guided ribonuclease activities for CRISPR-Cas9 systems.
    Gramelspacher MJ; Hou Z; Zhang Y
    Methods; 2020 Feb; 172():32-41. PubMed ID: 31228550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A scoutRNA Is Required for Some Type V CRISPR-Cas Systems.
    Harrington LB; Ma E; Chen JS; Witte IP; Gertz D; Paez-Espino D; Al-Shayeb B; Kyrpides NC; Burstein D; Banfield JF; Doudna JA
    Mol Cell; 2020 Aug; 79(3):416-424.e5. PubMed ID: 32645367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 Structures and Mechanisms.
    Jiang F; Doudna JA
    Annu Rev Biophys; 2017 May; 46():505-529. PubMed ID: 28375731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.
    Ganguly C; Rostami S; Long K; Aribam SD; Rajan R
    J Biol Chem; 2024 Jun; 300(6):107295. PubMed ID: 38641067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
    Jinek M; Chylinski K; Fonfara I; Hauer M; Doudna JA; Charpentier E
    Science; 2012 Aug; 337(6096):816-21. PubMed ID: 22745249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures of Neisseria meningitidis Cas9 Complexes in Catalytically Poised and Anti-CRISPR-Inhibited States.
    Sun W; Yang J; Cheng Z; Amrani N; Liu C; Wang K; Ibraheim R; Edraki A; Huang X; Wang M; Wang J; Liu L; Sheng G; Yang Y; Lou J; Sontheimer EJ; Wang Y
    Mol Cell; 2019 Dec; 76(6):938-952.e5. PubMed ID: 31668930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-dependent RNA targeting by CRISPR-Cas9.
    Strutt SC; Torrez RM; Kaya E; Negrete OA; Doudna JA
    Elife; 2018 Jan; 7():. PubMed ID: 29303478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic CRISPR RNA-Cas9-guided genome editing in human cells.
    Rahdar M; McMahon MA; Prakash TP; Swayze EE; Bennett CF; Cleveland DW
    Proc Natl Acad Sci U S A; 2015 Dec; 112(51):E7110-7. PubMed ID: 26589814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Introns to Express RNA Guides for Cas9- and Cpf1-Mediated Multiplex Genome Editing.
    Ding D; Chen K; Chen Y; Li H; Xie K
    Mol Plant; 2018 Apr; 11(4):542-552. PubMed ID: 29462720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging QM/MM and Molecular Dynamics Simulations to Decipher the Reaction Mechanism of the Cas9 HNH Domain to Investigate Off-Target Effects.
    Maghsoud Y; Jayasinghe-Arachchige VM; Kumari P; Cisneros GA; Liu J
    J Chem Inf Model; 2023 Nov; 63(21):6834-6850. PubMed ID: 37877218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time observation of Cas9 postcatalytic domain motions.
    Wang Y; Mallon J; Wang H; Singh D; Hyun Jo M; Hua B; Bailey S; Ha T
    Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33443184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.